AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31932382 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31932458 — intervention group
Group type: EXPERIMENTAL
Intervention: p.V59M genotype
Number of subjects: 0
Study 31932458 — intervention group
Group type: EXPERIMENTAL
Intervention: Other genotypes
Number of subjects: 0
Study 31932458 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea treatment
Number of subjects: 0
Study 31932458 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral MRI
Number of subjects: 0
Study 31932515 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg oral tablets
Number of subjects: 2
Study 31932515 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg subcutaneous monthly
Number of subjects: 2
Study 31932515 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg subcutaneous monthly
Number of subjects: 2
Study 31932515 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg oral tablets and Erenumab
Number of subjects: 2
Study 31932960 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 411
Study 31932960 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 411
Study 31932999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking training for 8 weeks
Number of subjects: 33
Study 31932999 — intervention group
Group type: COMPARATOR
Intervention: Free walking training for 8 weeks
Number of subjects: 33
Study 31933070 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 2235
Study 31934472 — intervention group
Group type: EXPERIMENTAL
Intervention: Migalastat
Number of subjects: 1
Study 31934592 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid atherosclerosis assessment by duplex ultrasonography
Number of subjects: 583
Study 31934592 — intervention group
Group type: COMPARATOR
Intervention: Prior cardiovascular event
Number of subjects: 583
Study 31934594 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial 10-mL 2% lidocaine injection
Number of subjects: 40
Study 31934594 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (no contents injected)
Number of subjects: 40
Study 31934809 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31934829 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) treatment, 88 sessions from January 2008 to April 2014.
Number of subjects: 70
Study 31934868 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal access with a tablet and tutorial, pre- and postuse surveys, in-person semistructured interviews.
Number of subjects: 97
Study 31934869 — intervention group
Group type: EXPERIMENTAL
Intervention: Coed Twitter support group
Number of subjects: 960
Study 31934869 — intervention group
Group type: EXPERIMENTAL
Intervention: Women-only Twitter support group
Number of subjects: 960
Study 31934869 — intervention group
Group type: COMPARATOR
Intervention: Usual quit-smoking care (control)
Number of subjects: 960
Study 31934886 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) testing using i-STAT
Number of subjects: 50
Study 31934886 — intervention group
Group type: COMPARATOR
Intervention: Standard laboratory analysis
Number of subjects: 50
Study 31934936 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 3 (subtype 3b)
Number of subjects: 997
Study 31934936 — intervention group
Group type: COMPARATOR
Intervention: HCV genotype 1
Number of subjects: 997
Study 31934936 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 3
Number of subjects: 997
Study 31935284 — intervention group
Group type: EXPERIMENTAL
Intervention: BEGEV regimen (bendamustine, gemcitabine, vinorelbine) followed by autologous stem cell transplantation (ASCT)
Number of subjects: 59
Study 31935284 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT after BEGEV regimen
Number of subjects: 59
Study 31935284 — intervention group
Group type: EXPERIMENTAL
Intervention: BEGEV regimen
Number of subjects: 59
Study 31935289 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum tumor diameter measurement
Number of subjects: 0
Study 31935746 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive forced oscillometry (FOT) using TremoFlo C-100 Airwave System™
Number of subjects: 155
Study 31935746 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with TTN
Number of subjects: 155
Study 31936256 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire items addressing Oral Health Locus of Control (OHLOC)
Number of subjects: 0
Study 31936677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of maladaptive emotion regulation strategies (t1)
Number of subjects: 272
Study 31936677 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender, higher self-efficacy (t1), lower depression (t1), lower performance and school anxiety (t1), lower social-interaction anxiety (t1), lower procrastination (t1)
Number of subjects: 272
Study 31936897 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium electroporation (Ca-EP)
Number of subjects: 7
Study 31936897 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin-based electrochemotherapy (ECT)
Number of subjects: 7
Study 31937118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution diffusion-weighted imaging (DWI)
Number of subjects: 55
Study 31937118 — intervention group
Group type: COMPARATOR
Intervention: Conventional diffusion-weighted imaging (DWI)
Number of subjects: 55
Study 31937266 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pneumatic compression stockings
Number of subjects: 15
Study 31937310 — intervention group
Group type: EXPERIMENTAL
Intervention: Caverstem 1.0 low dose
Number of subjects: 40
Study 31937310 — intervention group
Group type: EXPERIMENTAL
Intervention: Caverstem 1.0 high dose
Number of subjects: 40
Study 31937310 — intervention group
Group type: EXPERIMENTAL
Intervention: Caverstem 2.0
Number of subjects: 40
Study 31937310 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 31937474 — intervention group
Group type: EXPERIMENTAL
Intervention: CAREN system (8 sessions, twice weekly for 4 weeks)
Number of subjects: 4
Study 31937616 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0084 (45 mg/day)
Number of subjects: 47
Study 31937616 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0084 (various doses)
Number of subjects: 47
Study 31937616 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0084 (≥45 mg/day)
Number of subjects: 47
Study 31937616 — intervention group
Group type: EXPERIMENTAL
Intervention: GDC-0084
Number of subjects: 47
Study 31937615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib, lenalidomide, and methylprednisolone
Number of subjects: 28
Study 31938004 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day H
Number of subjects: 0
Study 31938004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31938786 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (reducing fat intake to 20% of energy and increasing fruit, vegetable, and grain intake)
Number of subjects: 1606
Study 31938786 — intervention group
Group type: COMPARATOR
Intervention: Usual diet comparison group
Number of subjects: 1606
Study 31938892 — intervention group
Group type: EXPERIMENTAL
Intervention: 295.0 ± 8.2 MBq of the novel PET radiopharmaceutical
Number of subjects: 5
Study 31939531 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin)
Number of subjects: 0
Study 31940024 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 33560
Study 31940024 — intervention group
Group type: COMPARATOR
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 33560
Study 31940346 — intervention group
Group type: EXPERIMENTAL
Intervention: SEARCH HTN screening
Number of subjects: 95000
Study 31940346 — intervention group
Group type: EXPERIMENTAL
Intervention: SEARCH clinic appointments for HTN+ participants
Number of subjects: 95000
Study 31940346 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to care for HTN+ participants
Number of subjects: 95000
Study 31940346 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up care for SEARCH clinic participants
Number of subjects: 95000
Study 31941468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilla participation
Number of subjects: 786
Study 31941468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilla participation among those not prenatally depressed
Number of subjects: 786
Study 31941468 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilla participation among those prenatally depressed
Number of subjects: 786
Study 31941516 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Feedback System (CFS)
Number of subjects: 0
Study 31941540 — intervention group
Group type: EXPERIMENTAL
Intervention: European Consortium of Lipodystrophies (ECLip) Registry
Number of subjects: 246
Study 31941657 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in the 1970s
Number of subjects: 23462
Study 31941657 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in the 1980s
Number of subjects: 23462
Study 31941657 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in the 1990s
Number of subjects: 23462
Study 31941953 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY) treatment
Number of subjects: 135
Study 31942173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg once daily for 2 years
Number of subjects: 254
Study 31942173 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily for 2 years
Number of subjects: 254
Study 31942173 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 254
Study 31942173 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 254
Study 31942264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated lesional radiotherapy with 60 Gy in 10 fractions (given simultaneously with whole-brain helical tomotherapy with 30 Gy in 10 fractions)
Number of subjects: 87
Study 31942264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated lesional radiotherapy with 60 Gy in 10 fractions
Number of subjects: 87
Study 31942430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection (IVI) of anti-VEGF (bevacizumab or ranibizumab) followed by a loose treat and extend regimen.
Number of subjects: 63
Study 31942430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue therapy of aflibercept (Group 2).
Number of subjects: 63
Study 31942430 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with three loading doses of either bevacizumab or ranibizumab.
Number of subjects: 63
Study 31943126 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging with indocyanine green (ICG) administered intravenously at 0.3 mg/kg bodyweight.
Number of subjects: 173
Study 31943126 — intervention group
Group type: COMPARATOR
Intervention: White-light laparoscopy alone.
Number of subjects: 173
Study 31943126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of white-light and NIR-ICG.
Number of subjects: 173
Study 31943126 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR fluorescence imaging with ICG for resection of deep infiltrating nodules.
Number of subjects: 173
Study 31943262 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) using SF-36 mental component summary T-score
Number of subjects: 876
Study 31943262 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) using SF-36 physical component summary T-score
Number of subjects: 876
Study 31943262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue using PROMIS Fatigue T-score
Number of subjects: 876
Study 31943262 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom burden using a 10-item Total Symptom Checklist
Number of subjects: 876
Study 31943262 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of symptoms reported
Number of subjects: 876
Study 31943262 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of APRI ≥1.50 and comorbidities with patient-reported outcomes
Number of subjects: 876
Study 31943262 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of Total Symptom Checklist score on regression models
Number of subjects: 876
Study 31943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) use
Number of subjects: 88
Study 31943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 88
Study 31943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Aetiology
Number of subjects: 88
Study 31943691 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 88
Study 31943691 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 88
Study 31943974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 587
Study 31943974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg (with dose escalation to 300 mg)
Number of subjects: 587
Study 31943974 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab (any dose)
Number of subjects: 587
Study 31945475 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline interrupter resistance (Rint) measurements
Number of subjects: 130
Study 31945475 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-bronchodilator response (BDR) measurements
Number of subjects: 130
Study 31945475 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Rint and sRaw in children with poorly or partially controlled asthma
Number of subjects: 130
Study 31948386 — intervention group
Group type: EXPERIMENTAL
Intervention: Societal perspective
Number of subjects: 355
Study 31948386 — intervention group
Group type: EXPERIMENTAL
Intervention: Third party payer perspective
Number of subjects: 355
Study 31948386 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dependency of the person with dementia
Number of subjects: 355
Study 31948386 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational level of the caregiver
Number of subjects: 355
Study 31948386 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's retirement status
Number of subjects: 355
Study 31948386 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life in caregivers
Number of subjects: 355
Study 31948438 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with HIV
Number of subjects: 275
Study 31948438 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable depression
Number of subjects: 275
Study 31948438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunger
Number of subjects: 275
Study 31948438 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy
Number of subjects: 275
Study 31948451 — intervention group
Group type: EXPERIMENTAL
Intervention: BPI-9016M (100 mg to 800 mg, QD dosing for 28 days)
Number of subjects: 20
Study 31949011 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation
Number of subjects: 80
Study 31949950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic posterior capsulorhexis
Number of subjects: 100
Study 31950251 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceval sutureless bioprosthesis
Number of subjects: 46
Study 31950251 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall expansion > 80%
Number of subjects: 46
Study 31950251 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional underexpansion
Number of subjects: 46
Study 31950310 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 20
Study 31950432 — intervention group
Group type: EXPERIMENTAL
Intervention: YAZ (3 mg drospirenone/20 μg ethinyl estradiol)
Number of subjects: 1921
Study 31951027 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02
Number of subjects: 0
Study 31951027 — intervention group
Group type: EXPERIMENTAL
Intervention: GZ17-6.02 combined with 5-fluorouracil
Number of subjects: 0
Study 31951149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab-rwlc
Number of subjects: 0
Study 31951215 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit2Heal smartphone app
Number of subjects: 59
Study 31951215 — intervention group
Group type: COMPARATOR
Intervention: QuitGuide (control)
Number of subjects: 59
Study 31951765 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with different antigen doses and aluminum-hydroxide adjuvant
Number of subjects: 628
Study 31951765 — intervention group
Group type: COMPARATOR
Intervention: RSV-PreF vaccine
Number of subjects: 628
Study 31951765 — intervention group
Group type: COMPARATOR
Intervention: haNEO1-reduced vaccines
Number of subjects: 628
Study 31952071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 25
Study 31952071 — intervention group
Group type: COMPARATOR
Intervention: Healthy control (HC) participants
Number of subjects: 25
Study 31952501 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1435
Study 31952501 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1435
Study 31952501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1435
Study 31952501 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab (both doses)
Number of subjects: 1435
Study 31952520 — intervention group
Group type: EXPERIMENTAL
Intervention: Insured patients
Number of subjects: 196
Study 31952520 — intervention group
Group type: COMPARATOR
Intervention: Uninsured patients
Number of subjects: 196
Study 31952543 — intervention group
Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 141
Study 31952626 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed gabapentin
Number of subjects: 401
Study 31952626 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-prescribed gabapentin
Number of subjects: 401
Study 31952626 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prescribed and non-prescribed gabapentin
Number of subjects: 401
Study 31952626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin use (overall)
Number of subjects: 401
Study 31952626 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin use (diverted)
Number of subjects: 401
Study 31952975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 3 mg/kg intravenously over 30 min every 2 weeks for up to 96 weeks
Number of subjects: 78
Study 31952975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 78
Study 31952983 — intervention group
Group type: EXPERIMENTAL
Intervention: LAD threshold of 40 mm
Number of subjects: 675
Study 31953079 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel plus gemcitabine
Number of subjects: 107
Study 31953313 — intervention group
Group type: EXPERIMENTAL
Intervention: Probody therapeutic CX-072
Number of subjects: 0
Study 31953669 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible bronchoscope (FB) intubation
Number of subjects: 420
Study 31953740 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg IV
Number of subjects: 20
Study 31953896 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 484
Study 31953927 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective mucosal irradiation (EMI)
Number of subjects: 46
Study 31954100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral colistin and neomycin decontamination
Number of subjects: 0
Study 31954102 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen use with activity
Number of subjects: 829
Study 31954102 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen use at rest
Number of subjects: 829
Study 31954102 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing Dlco
Number of subjects: 829
Study 31954102 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-Age-Lung Physiology score
Number of subjects: 829
Study 31954102 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Physiologic Index scores
Number of subjects: 829
Study 31954144 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media use
Number of subjects: 3612
Study 31954144 — intervention group
Group type: EXPERIMENTAL
Intervention: Television use
Number of subjects: 3612
Study 31954144 — intervention group
Group type: EXPERIMENTAL
Intervention: Video gaming
Number of subjects: 3612
Study 31954227 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Navi© Programme (SN©P)
Number of subjects: 0
Study 31954227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse training for SN©P
Number of subjects: 0
Study 31954227 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-related Sense of Coherence (Work-SoC) scale
Number of subjects: 0
Study 31954624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nazartinib (EGF816) 150 mg once daily (tablet)
Number of subjects: 180
Study 31954624 — intervention group
Group type: EXPERIMENTAL
Intervention: Nazartinib (EGF816)
Number of subjects: 180
Study 31954643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 24
Study 31954643 — intervention group
Group type: COMPARATOR
Intervention: Left Bundle Branch Block (LBBB)
Number of subjects: 24
Study 31954661 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin strut bioresorbable polymer sirolimus-eluting stent (BP SES)
Number of subjects: 1000000
Study 31954661 — intervention group
Group type: COMPARATOR
Intervention: Thin strut durable polymer everolimus-eluting stent (DP EES)
Number of subjects: 1000000
Study 31954677 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter leak closure with detachable coils
Number of subjects: 30
Study 31955915 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential threat conditioning and extinction paradigm
Number of subjects: 351
Study 31955915 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance response to conditioned (CS+, CS-) and unconditioned threat stimuli
Number of subjects: 351
Study 31955915 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance response
Number of subjects: 351
Study 31955915 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditioned responding
Number of subjects: 351
Study 31955915 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipatory responding to potential threat
Number of subjects: 351